MRSN
Income statement / Annual
Last year (2024), Mersana Therapeutics, Inc.'s total revenue was $40.50 M,
an increase of 9.88% from the previous year.
In 2024, Mersana Therapeutics, Inc.'s net income was -$69.19 M.
See Mersana Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$40.50 M |
$36.86 M |
$26.58 M |
$43,000.00 |
$828,000.00 |
$42.12 M |
$10.59 M |
$17.55 M |
$25.17 M |
$10.36 M |
| Cost of Revenue |
$0.00
|
$148.27 M
|
$927,000.00
|
$132.01 M
|
$67.04 M
|
$55.04 M
|
$59.92 M
|
$928,000.00
|
$32.01 M
|
$21.35 M
|
| Gross Profit |
$40.50 M
|
-$111.41 M
|
$25.65 M
|
-$131.97 M
|
-$66.21 M
|
-$12.92 M
|
-$49.32 M
|
$16.62 M
|
-$6.84 M
|
-$10.99 M
|
| Gross Profit Ratio |
1
|
-3.02
|
0.97
|
-3069.07
|
-79.96
|
-0.31
|
-4.66
|
0.95
|
-0.27
|
-1.06
|
| Research and Development Expenses |
$73.02 M
|
$148.27 M
|
$173.39 M
|
$132.01 M
|
$67.04 M
|
$55.04 M
|
$59.92 M
|
$46.70 M
|
$32.01 M
|
$21.35 M
|
| General & Administrative Expenses |
$40.81 M
|
$59.54 M
|
$56.96 M
|
$36.89 M
|
$21.90 M
|
$17.28 M
|
$16.33 M
|
$10.46 M
|
$6.98 M
|
$5.35 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$40.81 M
|
$59.54 M
|
$56.96 M
|
$36.89 M
|
$21.90 M
|
$17.28 M
|
$16.33 M
|
$10.46 M
|
$6.98 M
|
$5.35 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$445,000.00
|
-$1.20 M
|
$0.00
|
$0.00
|
$1.40 M
|
$0.00
|
$0.00
|
-$89,000.00
|
| Operating Expenses |
$113.83 M
|
$36.86 M
|
$230.35 M
|
$168.90 M
|
$88.94 M
|
$72.32 M
|
$76.25 M
|
$57.16 M
|
$38.99 M
|
$26.70 M
|
| Cost And Expenses |
$113.83 M
|
$207.81 M
|
$230.35 M
|
$168.90 M
|
$88.94 M
|
$72.32 M
|
$76.25 M
|
$57.16 M
|
$38.99 M
|
$26.70 M
|
| Interest Income |
$8.44 M
|
$12.07 M
|
$2.88 M
|
$65,000.00
|
$424,000.00
|
$2.23 M
|
$1.40 M
|
$910,000.00
|
$121,000.00
|
$2,000.00
|
| Interest Expense |
$3.87 M
|
$4.07 M
|
$3.33 M
|
$1.27 M
|
$359,000.00
|
$234,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.63 M
|
$1.52 M
|
$927,000.00
|
$855,000.00
|
$1.01 M
|
$1.25 M
|
$1.26 M
|
$928,000.00
|
$655,000.00
|
$297,000.00
|
| EBITDA |
-$63.27 M |
-$166.08 M |
-$199.96 M |
-$167.94 M |
-$86.68 M |
-$26.73 M |
-$63.00 M |
-$37.78 M |
-$13.17 M |
-$16.04 M |
| EBITDA Ratio |
-1.56
|
-4.51
|
-7.67
|
-3926.93
|
-104.68
|
-0.66
|
-6.2
|
-2.21
|
-0.52
|
-1.55
|
| Operating Income Ratio |
-1.81
|
-4.64
|
-7.7
|
-3946.81
|
-105.9
|
-0.69
|
-6.2
|
-2.26
|
-0.55
|
-1.58
|
| Total Other Income/Expenses Net |
$4.56 M
|
-$713,000.00
|
-$445,000.00
|
-$1.20 M
|
$65,000.00
|
$1.99 M
|
$1.40 M
|
$910,000.00
|
$121,000.00
|
-$87,000.00
|
| Income Before Tax |
-$68.77 M
|
-$171.67 M
|
-$204.21 M
|
-$170.06 M
|
-$88.05 M
|
-$28.21 M
|
-$64.26 M
|
-$38.71 M
|
-$13.70 M
|
-$16.43 M
|
| Income Before Tax Ratio |
-1.7
|
-4.66
|
-7.68
|
-3954.88
|
-106.33
|
-0.67
|
-6.07
|
-2.21
|
-0.54
|
-1.59
|
| Income Tax Expense |
$418,000.00
|
$0.00
|
$3.33 M
|
-$855,000.00
|
$359,000.00
|
-$1.01 M
|
$1.40 M
|
$0.00
|
$0.00
|
-$2,000.00
|
| Net Income |
-$69.19 M
|
-$171.67 M
|
-$207.54 M
|
-$169.21 M
|
-$88.40 M
|
-$27.20 M
|
-$64.26 M
|
-$38.71 M
|
-$13.70 M
|
-$16.43 M
|
| Net Income Ratio |
-1.71
|
-4.66
|
-7.81
|
-3935
|
-106.77
|
-0.65
|
-6.07
|
-2.21
|
-0.54
|
-1.59
|
| EPS |
-0.56 |
-1.48 |
-2.22 |
-2.4 |
-1.44 |
-0.63 |
-2.79 |
-3.22 |
-0.78 |
-0.94 |
| EPS Diluted |
-0.56 |
-1.48 |
-2.22 |
-2.4 |
-1.44 |
-0.63 |
-2.79 |
-3.22 |
-0.78 |
-0.94 |
| Weighted Average Shares Out |
$122.54 M
|
$116.11 M
|
$93.65 M
|
$70.58 M
|
$61.49 M
|
$43.40 M
|
$23.03 M
|
$12.02 M
|
$17.49 M
|
$17.49 M
|
| Weighted Average Shares Out Diluted |
$122.54 M
|
$116.11 M
|
$93.65 M
|
$70.58 M
|
$61.49 M
|
$43.49 M
|
$23.03 M
|
$12.02 M
|
$17.49 M
|
$17.49 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
